#South Korea #Rznomics #Seongnam #RNA Therapeutics #Lilly Gateway

Rznomics Partners with Lilly Gateway Labs

Rznomics Inc., a South Korean biopharmaceutical firm focusing on RNA-based gene therapies, recently announced its collaboration with Lilly Gateway Labs (LGL) in San Diego, California. This partnership signifies a strategic move toward accelerating the development of RNA therapeutics, a cutting-edge area in the pharmaceutical industry.

What is Lilly Gateway Labs?

Lilly Gateway Labs serves as an innovative hub designed for biotechnology companies seeking to advance their projects through shared resources and expertise. By being part of this well-established ecosystem, Rznomics gains access to state-of-the-art wet lab facilities and the opportunity to collaborate directly with seasoned scientists and executives from Eli Lilly. This collaboration forms part of the broader Lilly Catalyze360 initiative, which includes multiple programs like Lilly Ventures, Lilly ExploRD, and Lilly TuneLab, each contributing to biotech innovation through funding, state-of-the-art laboratory space, and advanced research capabilities.

Rznomics’ Vision and Objectives

By joining LGL, Rznomics aims to boost its candidate discovery and development efforts, leveraging its extensive database of over 200 disease targets. This is a significant step, as the company is determined to build a global clinical infrastructure to support its clinical pipelines. Furthermore, it is looking to foster strategic partnerships and recruit top-tier research and development talent in the United States.

CEO Seong-Wook Lee emphasizes that this partnership marks a crucial milestone for the company and its proprietary RNA platform. Lee stated, "Joining Lilly Gateway Labs in San Diego represents a meaningful milestone for Rznomics' proprietary RNA platform. We intend to advance the development and commercialization of our RNA therapeutics by active collaboration with the global biotech ecosystem."

Background on Rznomics

Rznomics Inc. specializes in the development of RNA-based gene therapies and has developed a proprietary trans-splicing ribozyme platform. This unique technology allows for precise RNA editing with wide-ranging applications in treating various diseases. The company gained considerable attention in May 2025 when it entered into a research collaboration and license agreement with Eli Lilly for the development of a cutting-edge RNA editing therapeutic. Following this, Rznomics successfully listed on the KOSDAQ market in December 2025.

This partnership with Lilly Gateway Labs enables Rznomics to further enhance its capability and drive innovation within the RNA therapeutics landscape, which is crucial for addressing unmet medical needs across a spectrum of diseases.

Conclusion

The collaboration between Rznomics and Lilly Gateway Labs marks an exciting chapter in the evolution of RNA therapeutics. With shared resources, expertise, and innovative aspirations, both organizations are poised to make significant strides toward the development of life-changing therapies that could ultimately benefit millions worldwide. As Rznomics continues to expand its research activities and partnerships, the future of RNA therapeutics looks increasingly promising.